Garner Megan, Ahmed Eltayeb, Gatiss Sarah, West Douglas
Department of Thoracic Surgery, University Hospitals Bristol, Bristol, UK.
Department of Obstetrics and Gynaecology, City Hospitals Sunderland, Sunderland, UK.
Interact Cardiovasc Thorac Surg. 2018 Feb 1;26(2):319-322. doi: 10.1093/icvts/ivx319.
A best evidence topic in thoracic surgery was written according to a structured protocol. The question addressed was whether hormonal manipulation with gonadotrophin-releasing hormone analogues reduces the risk of recurrent catamenial pneumothorax after surgery, compared with surgery alone. Altogether 819 papers were found using the reported search, of which 7 represented the best evidence to answer the clinical question. The authors, date, journal, country of publication, study type, level of evidence, patient group studied, relevant outcomes and results of these papers are tabulated. Of the 7 papers selected, 6 demonstrated a reduction in recurrence of catamenial pneumothorax with the use of gonadotrophin-releasing hormone analogues, whereas in the single paper where surgery alone was performed, no evidence of recurrence was demonstrated. We therefore conclude that, based on very small retrospective observational studies, gonadotrophin-releasing hormone analogues used as an adjunct to surgical intervention may reduce the risk of recurrent pneumothorax, when compared with either no hormonal therapy or oestrogen-progesterone therapy, but should be initiated and supervised by gynaecologists who will be familiar with the therapy and the potential side effects.
根据结构化方案撰写了一篇胸外科最佳证据主题文章。探讨的问题是,与单纯手术相比,使用促性腺激素释放激素类似物进行激素治疗是否能降低手术后月经性气胸复发的风险。通过报告的检索共找到819篇论文,其中7篇代表了回答该临床问题的最佳证据。现将这些论文的作者、日期、期刊、出版国家、研究类型、证据水平、研究的患者组、相关结局和结果制成表格。在所选的7篇论文中,6篇表明使用促性腺激素释放激素类似物可降低月经性气胸的复发率,而在仅进行手术的那篇论文中,未显示复发的证据。因此,我们得出结论,基于非常小的回顾性观察研究,与不进行激素治疗或雌激素 - 孕激素治疗相比,促性腺激素释放激素类似物作为手术干预的辅助手段,可能会降低气胸复发的风险,但应由熟悉该治疗方法及其潜在副作用的妇科医生启动并监督使用。